Bank of New York Mellon Corp Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Bank of New York Mellon Corp raised its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 18.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 488,721 shares of the biotechnology company’s stock after buying an additional 77,510 shares during the period. Bank of New York Mellon Corp owned approximately 0.34% of Aurinia Pharmaceuticals worth $2,791,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in AUPH. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $30,000. Tidemark LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $39,000. Eagle Asset Management Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $92,000. Virtu Financial LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 1st quarter worth approximately $78,000. Finally, Sierra Summit Advisors LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $202,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Stock Up 6.8 %

Shares of AUPH opened at $7.03 on Monday. The firm has a market cap of $1.01 billion, a PE ratio of -16.35 and a beta of 1.44. The company’s fifty day moving average is $6.06 and its two-hundred day moving average is $5.55. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.05. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. Aurinia Pharmaceuticals’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.08) EPS. Analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on AUPH shares. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, September 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Insider Activity at Aurinia Pharmaceuticals

In related news, insider Scott Michael Habig sold 18,249 shares of Aurinia Pharmaceuticals stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the transaction, the insider now owns 456,338 shares in the company, valued at approximately $2,423,154.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.30% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.